RE:ONCY's pelareorep enables CAR-T trafficking in solid tumorsIn order to achieve efficacious therapeutic responses, a CAR-T cell antigen-binding domain must bind its target epitope and reach a minimum threshold level to induce CAR-T cell activation and cytokine secretion. At the same time, however, there is also some threshold level of activation that when surpassed produces toxic levels of cytokines and immune system activation. In other words, the CAR-T cell must remain within its therapeutic window to be clinically effective as overshooting the therapeutic window will lead to toxicity. From an engineering perspective, the degree of CAR-T cell activation and activation kinetics are influenced by several factors including but not limited to the level of tumor antigen expressed on malignant cells, tumor burden, antigen binding domain’s affinity to its target epitope, and the CAR’s costimulatory elements.
Therefore it is critical that the CAR-T therapy be efficiently trafficked to the tumor cell surface to be effective, which is synergistically enabled when combined with ONCY's pelareorep.